Title | Screening for autism spectrum disorders in extremely preterm infants. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Stephens BE, Bann CM, Watson VE, Sheinkopf SJ, Peralta-Carcelen M, Bodnar A, Yolton K, Goldstein RF, Dusick AM, Wilson-Costello DE, Acarregui MJ, Pappas A, Adams-Chapman I, McGowan EC, Heyne RJ, Hintz SR, Ehrenkranz RA, Fuller J, Das A, Higgins RD, Vohr BR |
Corporate Authors | Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network |
Journal | J Dev Behav Pediatr |
Volume | 33 |
Issue | 7 |
Pagination | 535-41 |
Date Published | 2012 Sep |
ISSN | 1536-7312 |
Keywords | Child Development Disorders, Pervasive, Cohort Studies, Developmental Disabilities, Diagnosis, Differential, Female, Humans, Infant, Infant, Newborn, Infant, Premature, Male, Mass Screening, Psychiatric Status Rating Scales, Surveys and Questionnaires |
Abstract | BACKGROUND: Extremely preterm (EP) infants screen positive for autism spectrum disorders (ASD) at high rates. However, it is not clear whether this is because of high rates of ASD in EPs or to high rates of false-positive screens for ASD in children with a high rate of underlying neurodevelopmental impairments. Combining a parent questionnaire designed to distinguish developmental delay from ASD with direct observation of infant behavior may more accurately screen for ASD in EPs. OBJECTIVES: To determine rates of positive screen for ASD at 18 to 22 months(m) in EPs using 3 screens; to determine factors associated with a positive screen. METHODS: Five hundred fifty-four infants born <27 weeks were screened at 18 to 22 m using the Pervasive Developmental Disorders Screening test, second edition Stage 2, and the response to name and response to joint attention items from the Autism Diagnostic Observation Schedule. Infants with severe cerebral palsy, deafness, and blindness were excluded. Associations between positive screen and neonatal/ infant characteristics were determined. RESULTS: Of 554 infants, 113 (20%) had ≥ 1 positive screen. 10% had a positive Pervasive Developmental Disorders Screening test, second edition, 6% response to name, 9% response to joint attention; in only 1 % all 3 screens were positive. Positive screen was associated with male gender, more hospital days, white race, lower maternal education, abnormal behavioral scores, and cognitive/ language delay. CONCLUSIONS: The use of 3 screens for ASD in EPs results in higher screen positive rates than use of 1 screen alone. Diagnostic confirmation is needed before true rates of ASD in EPs are known. |
DOI | 10.1097/DBP.0b013e31825fd0af |
Alternate Journal | J Dev Behav Pediatr |
PubMed ID | 22926660 |
PubMed Central ID | PMC3434239 |
Grant List | U10 HD021385 / HD / NICHD NIH HHS / United States UL1 RR025764 / RR / NCRR NIH HHS / United States U10 HD053124 / HD / NICHD NIH HHS / United States U10 HD053119 / HD / NICHD NIH HHS / United States U10 HD021364 / HD / NICHD NIH HHS / United States M01 RR000039 / RR / NCRR NIH HHS / United States M01 RR000030 / RR / NCRR NIH HHS / United States M01 RR000633 / RR / NCRR NIH HHS / United States UG1 HD034216 / HD / NICHD NIH HHS / United States M01 RR000997 / RR / NCRR NIH HHS / United States UG1 HD068278 / HD / NICHD NIH HHS / United States U10 HD027856 / HD / NICHD NIH HHS / United States UL1 RR024139 / RR / NCRR NIH HHS / United States U10 HD027880 / HD / NICHD NIH HHS / United States U10 HD053109 / HD / NICHD NIH HHS / United States M01 RR008084 / RR / NCRR NIH HHS / United States UL1 TR001449 / TR / NCATS NIH HHS / United States UG1 HD053089 / HD / NICHD NIH HHS / United States M01 RR000750 / RR / NCRR NIH HHS / United States M01 RR000059 / RR / NCRR NIH HHS / United States U10 HD040689 / HD / NICHD NIH HHS / United States U10 HD040492 / HD / NICHD NIH HHS / United States M01 RR000054 / RR / NCRR NIH HHS / United States U10 HD027853 / HD / NICHD NIH HHS / United States U10 HD027904 / HD / NICHD NIH HHS / United States UL1 TR000454 / TR / NCATS NIH HHS / United States U10 HD027871 / HD / NICHD NIH HHS / United States UL1 RR024148 / RR / NCRR NIH HHS / United States UL1 TR000041 / TR / NCATS NIH HHS / United States U10 HD027851 / HD / NICHD NIH HHS / United States M01 RR000032 / RR / NCRR NIH HHS / United States UG1 HD053109 / HD / NICHD NIH HHS / United States M01 RR000064 / RR / NCRR NIH HHS / United States M01 RR000070 / RR / NCRR NIH HHS / United States M01 RR000080 / RR / NCRR NIH HHS / United States U10 HD034216 / HD / NICHD NIH HHS / United States U10 HD036790 / HD / NICHD NIH HHS / United States M01 RR000125 / RR / NCRR NIH HHS / United States M01 RR006022 / RR / NCRR NIH HHS / United States U10 HD053089 / HD / NICHD NIH HHS / United States |